{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:08:06Z","timestamp":1761311286876},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00439","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T22:09:38Z","timestamp":1506550178000},"page":"2199-2204","source":"Crossref","is-referenced-by-count":5,"title":["Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells"],"prefix":"10.1248","volume":"40","author":[{"given":"Mika","family":"Hosokawa","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Iwakawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kobe Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Shinjo K, Kondo Y. Targeting cancer epigenetics: linking basic biology to clinical medicine. Adv. Drug Deliv. Rev.<\/i>, 95<\/b>, 56\u201364 (2015)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.<\/i>, 28<\/b>, 1069\u20131078 (2010).","DOI":"10.1038\/nbt.1678"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat.<\/i>, 15<\/b>, 98\u2013105 (2012).","DOI":"10.1016\/j.drup.2012.03.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tanaka S, Hosokawa M, Yonezawa T, Hayashi W, Ueda K, Iwakawa S. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. Biol. Pharm. Bull.<\/i>, 38<\/b>, 435\u2013440 (2015).","DOI":"10.1248\/bpb.b14-00695"},{"key":"5","unstructured":"5) Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin. Epigenetics<\/i>, 7<\/b>, 127 (2015)."},{"key":"6","unstructured":"6) Nie J, Liu L, Li X, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. Cancer Lett.<\/i>, 354<\/b>, 12\u201320 (2014)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol. Pharm. Bull.<\/i>, 37<\/b>, 67\u201373 (2014).","DOI":"10.1248\/bpb.b13-00574"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther.<\/i>, 87<\/b>, 227\u2013253 (2000).","DOI":"10.1016\/S0163-7258(00)00086-3"},{"key":"9","unstructured":"9) Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, Schinzari G, Leonardo GD, D\u2019Argento E, Trigila N, Cassano A. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro<\/i> evidence and a phase I dose-escalating clinical trial. Br. J. Cancer<\/i>, 96<\/b>, 21\u201328 (2007)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. Oncol. Rep.<\/i>, 24<\/b>, 1509\u20131514 (2010).","DOI":"10.3892\/or_00001012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via<\/i> activation of p21 gene expression leading to G2\/M cycle arrest. Mol. Pharm.<\/i>, 10<\/b>, 337\u2013352 (2013).","DOI":"10.1021\/mp3004622"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ye XN, Zhou XP, Wei JY, Xu GX, Li Y, Mao LP, Huang J, Ren YL, Mei C, Wang JH, Lou YJ, Ma LY, Yu WJ, Ye L, Xie LL, Luo YW, Hu C, Niu LM, Dou MH, Jin J, Tong HY. Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leuk. Lymphoma<\/i>, 57<\/b>, 1311\u20131318 (2016).","DOI":"10.3109\/10428194.2015.1091931"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S. In vitro<\/i> schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol.<\/i>, 55<\/b>, 595\u2013601 (2005).","DOI":"10.1007\/s00280-004-0966-z"},{"key":"14","unstructured":"14) Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy\u2013chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys.<\/i>, 5<\/b>, 85\u201391 (1979)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev.<\/i>, 58<\/b>, 621\u2013681 (2006).","DOI":"10.1124\/pr.58.3.10"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Takai N, Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet. Gynecol. Int.<\/i>, 2010<\/b>, 923824 (2010).","DOI":"10.1155\/2010\/923824"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O\u2019Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer WF, Mariadason JM, Sieber OM. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res.<\/i>, 74<\/b>, 3238\u20133247 (2014).","DOI":"10.1158\/0008-5472.CAN-14-0013"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Futschik M, Jeffs A, Pattison S, Kasabov N, Sullivan M, Merrie A, Reeve A. Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines. Genome Lett.<\/i>, 1<\/b>, 26\u201334 (2002).","DOI":"10.1166\/gl.2002.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Linnekamp JF, Butter R, Spijker R, Medema JP, van Laarhoven HW. Clinical and biological effects of demethylating agents on solid tumours\u2014a systematic review. Cancer Treat. Rev.<\/i>, 54<\/b>, 10\u201323 (2017).","DOI":"10.1016\/j.ctrv.2017.01.004"},{"key":"20","unstructured":"20) Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res.<\/i>, 63<\/b>, 7291\u20137300 (2003)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Asgar MA, Senawong G, Sripa B, Senawong T. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. Int. J. Oncol.<\/i>, 48<\/b>, 409\u2013420 (2016).","DOI":"10.3892\/ijo.2015.3240"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hrebackova J, Hrabeta J, Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr. Drug Targets<\/i>, 11<\/b>, 361\u2013379 (2010).","DOI":"10.2174\/138945010790711923"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D\u2019Angelo G, Franco R, Budillon A, Gennaro ED. Valproic acid potentiates the anticancer activity of capecitabine in vitro<\/i> and in vivo<\/i> in breast cancer models via<\/i> induction of thymidine phosphorylase expression. Oncotarget<\/i>, 7<\/b>, 7715\u20137731 (2016).","DOI":"10.18632\/oncotarget.6802"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Brodie SA, Brandes JC. Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev. Anticancer Ther.<\/i>, 14<\/b>, 1097\u20131100 (2014).","DOI":"10.1586\/14737140.2014.940329"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zhu X, Liu X, Cheng Z, Zhu J, Xu L, Wang F, Qi W, Yan J, Liu N, Sun Z, Liu H, Peng X, Hao Y, Zheng N, Wu Q. Quantitative analysis of global proteome and lysine acetylome reveal the differential impacts of VPA and SAHA on HL60 cells. Sci. Rep.<\/i>, 6<\/b>, 19926 (2016).","DOI":"10.1038\/srep19926"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Meyners C, Baud MG, Fuchter MJ, Meyer-Almes FJ. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors. Anal. Biochem.<\/i>, 460<\/b>, 39\u201346 (2014).","DOI":"10.1016\/j.ab.2014.05.014"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Li K, Hu C, Mei C, Ren Z, Vera JC, Zhuang Z, Jin J, Tong H. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target. J. Transl. Med.<\/i>, 12<\/b>, 167 (2014).","DOI":"10.1186\/1479-5876-12-167"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Flis S, Gnyszka A, Flis K. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLOS ONE<\/i>, 9<\/b>, e92305 (2014).","DOI":"10.1371\/journal.pone.0092305"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Flis S, Gnyszka A, Misiewicz-Krzemi\u0144ska I, Sp\u0142awi\u0144ski J. Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int.<\/i>, 9<\/b>, 10 (2009).","DOI":"10.1186\/1475-2867-9-10"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) F\u00fcller M, Klein M, Schmidt E, Rohde C, G\u00f6llner S, Schulze I, Qianli J, Berdel WE, Edemir B, M\u00fcller-Tidow C, Tschanter P. 5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. Int. J. Oncol.<\/i>, 46<\/b>, 1192\u20131204 (2015).","DOI":"10.3892\/ijo.2014.2792"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP. Epigenetic synergy between decitabine and platinum derivatives. Clin. Epigenetics<\/i>, 7<\/b>, 97 (2015).","DOI":"10.1186\/s13148-015-0131-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, L\u00fcbbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia<\/i>, 23<\/b>, 1019\u20131028 (2009).","DOI":"10.1038\/leu.2008.397"},{"key":"33","unstructured":"33) Hsieh YY, Huang TC, Lo HL, Jhan JY, Chen ST, Yang PM. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine. Oncotarget<\/i>, 7<\/b>, 27363\u201327378 (2016)."}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/12\/40_b17-00439\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T01:26:14Z","timestamp":1570152374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/12\/40_b17-00439\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00439","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}